Junhe Bio Completes Tens of Millions RMB Strategic Financing Round Led by Shijiazhuang Pharma-GF Pioneer Fund, WinX Capital Serves as Exclusive Financial Advisor for Multiple Rounds

Recently,Junhemeng Biopharmaceutical (Hangzhou) Co., Ltd. (hereinafter referred to as “Junhemeng” or the “Company”) has completed a strategic financing round amounting to tens of millions of yuan, with exclusive investment from CSPC Guofang Pioneer Fund. WinX Capital has served as the exclusive financial advisor across multiple consecutive rounds.The proceeds from this round of financing will be used forAdvance the development of the company’s product pipeline, deepen technological deployment in both serious healthcare and consumer healthcare sectors, and accelerate clinical progress, regulatory submissions, and market promotion of the company’s product portfolio.

Junhemeng was established in November 2020. It is a biotechnology company focused on the development of innovative products in the fields of recombinant protein-based therapeutics and synthetic biology. Leveraging years of experience in the research, development, and industrialization of recombinant protein drugs, the company has accumulated core technologies, platforms, and talent covering the entire product development lifecycle, thereby establishing a comprehensive system for technology and product development.

The company’s R&D pipeline is strategically focused on frontier protein therapeutics with substantial market potential, spanning serious medical care, consumer healthcare, and metabolic disorders. It has achieved large-scale manufacturing of high-end recombinant protein products, including bulk solutions and formulations of recombinant human type I/III collagen, as well as recombinant botulinum toxin type A. Its technological capabilities and industrialization progress are at the international forefront. Notably, the core product, recombinant human growth hormone injection, has completed Phase III clinical trials. Recombinant botulinum toxin type A recently administered the first dose to a subject in its Phase III clinical trial for the indication of moderate-to-severe glabellar lines in adults. Meanwhile, its Phase II clinical trial for the treatment of post-stroke upper limb spasticity in adults is nearing completion, paving the way for entry into Phase III clinical trials.

Recently, at the 20th MEVOS International Medical Aesthetics Conference held in Hangzhou, Junhemeng Biopharmaceutical made a remarkable debut with its latest synthetic biology research achievements and innovative products. As a biotechnology enterprise focusing on both serious medical care and consumer healthcare, its three core product series—Recombinant Botulinum Toxin Type A for Injection (Jianshutuo), Recombinant Human Collagen Series, and Growth Hormone Series—became the center of attention due to their cutting-edge innovative technologies and significant market potential.

Recombinant Botulinum Toxin Type A for Injection (Junshutuo)

Recombinant Human Collagen Repair Solution (Junkena)

Cross-linked Recombinant Human Type III Collagen Filler (35 mg/mL)

Cross-linked Recombinant Human Type I Collagen Filler (35mg/ml)

Recombinant Human Growth Hormone Injection (Junshengmeng)

During the exhibition, the R&D team of Junhemeng delivered two keynote technical presentations, systematically introducing the company’s research and development efforts and strategic layout in the field of biomedical materials. The sessions provided an in-depth analysis of the latest industry R&D trends, attracting a large audience of professionals. These presentations fully demonstrated Junhemeng’s technological prowess and industry leadership in synthetic biology, consumer healthcare, and serious medical care.

The 2025 MedWorld Conference Concluded Successfully; Junhemeng Reaffirms Its Strong Industry Competitiveness with Innovative Technologies and Superior Products. Moving forward, Junhemeng will continue to deepen its practical applications in both serious medical care and consumer healthcare, further accelerating the clinical development and regulatory submission of its core product pipeline to benefit patients and users at the earliest opportunity.

JunhemengCEOXu Kui stated: We sincerely appreciate CSPC Guofang Pioneer Fund’s recognition and support for the company. Since our inception, we have remained focused on addressing unmet clinical needs in both serious medical care and consumer healthcare, with independent R&D as our core driving force, building a comprehensive pipeline covering recombinant protein therapeutics throughout their entire life cycle.lifecycle technology platform and product pipeline. In the future, we will continue to deepen breakthroughs in innovative technologies, accelerate the development of our product pipeline and the process of filing for market approval, so as to provide higher-quality products to the market. We believe that with the team andWith the joint efforts of investment institutions, the company is poised to become a leader in the field of recombinant protein therapeutics.

Guofang Innovation Industry Partner Wei Yaguang stated: With the continuous expansion of indications, recombinant proteins have broad application prospects in both the serious medical and consumer healthcare markets. Junhemeng, through its past experience in recombinant botulinum toxin, recombinant human collagen, and recombinantExplorations, iterations, and achievements in core areas such as human growth hormone demonstrate the company’s robust and sustainable R&D capabilities. The exploration of the company’s recombinant botulinum toxin in the field of serious medicine will also have the opportunity to generate stronger synergies with the industrial ecosystem resources of CSPC Guofang Pioneer Fund. We will fully support Junhemeng Biopharmaceutical (Hangzhou) Co., Ltd. in continuing to advance its initiatives.The company's commercialization journey has propelled it to become a global leader in recombinant protein therapeutics.

WinX CapitalFounding Partner Zou GuowenIndicate: WinX Capital is honored to serve as the long-term capital partner of Junhemeng Biopharmaceutical (Hangzhou) Co., Ltd. and to continue leading its subsequent financing rounds. We sincerely appreciate the trust placed in WinX Capital by both the company and its investors. As a recombinant proteinAs an active participant in the highly competitive pharmaceutical sector, we possess profound insights into both serious healthcare and consumer healthcare industries, and have established an internationally leading innovative technology platform with independent intellectual property rights. We believe that the participation of CSPC Guofang Pioneer Fund will effectively safeguard the Company’s continuous R&D innovation and strengthen its industrial layout, thereby facilitating its growth into a leading recombinant protein therapeutic enterprise in the industry.

The CSPC-Guofang Pioneer Fund is one of the CVC industrial chain fund series managed by Guofang Innovation. Jointly initiated by Guofang and CSPC Pharmaceutical Group, a leading enterprise in China’s biopharmaceutical industry, the fund has received support from the Shanghai State-owned Capital Investment Pioneer Biomedical Fund of Funds, CPIC Health Industry Fund, and Tailong Investment, with a total committed capital of RMB 1.01 billion. By leveraging CSPC’s deep industrial expertise and pharmaceutical innovation resources, along with Guofang’s extensive experience in managing industrial chain funds and its robust industrial ecosystem, the CSPC-Guofang Pioneer Fund will fully capitalize on its advantages in project sourcing, industrial validation, and synergistic empowerment. Based in Shanghai and extending its reach across the Yangtze River Delta, the fund aims to build a globally competitive biopharmaceutical industrial cluster.

WinX Capital is a leading investment bank in China’s healthcare industry, headquartered in Beijing and Shanghai, with offices in Shenzhen and Hangzhou. It has received numerous accolades, including Qimingpian’s “No. 1 Financial Advisor in the Healthcare Sector for 2024,” Diyixinsheng’s “No. 1 Financial Advisory Firm in the Healthcare Sector from 2022 to 2024,” and VCBeat’s “Annual Healthcare Financial Advisor among the Top 100 Future Healthcare Companies from 2022 to 2024.”